Prostate cancer, version 1.2014.
J Natl Compr Canc Netw
; 11(12): 1471-9, 2013 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-24335682
ABSTRACT
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
Tipo de estudo:
Guideline
Limite:
Humans
/
Male
Idioma:
En
Revista:
J Natl Compr Canc Netw
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2013
Tipo de documento:
Article